Homa Yeganegi serves as senior vice president, project team leader and head of Medical Affairs for Turning Point Therapeutics. She is responsible for global product development of lead drug candidate repotrectinib and the ongoing physician education associated with the company’s three clinical-stage drug candidates in four ongoing clinical studies.
Ms. Yeganegi has extensive experience building and leading oncology-focused global Medical Affairs teams, most recently as senior vice president and global program leader at Halozyme, where she was responsible for commercialization strategy and operational planning for the company’s investigational oncology drug candidate. Ms. Yeganegi previously served as vice president of Global Medical Affairs at Clovis Oncology where she successfully supported pre-launch activities for rociletinib in non-small lung cancer in the U.S. and Europe. She also built and led oncology-focused Global Medical Affairs teams at Exelixis and Onyx Pharmaceuticals.
She received her B.S. in Biology from the University of Tehran, Iran, her M.S. in Neuroanatomy from the University of Western Australia and is completing her Ph.D. in Health Sciences.